SCHEMBL587488

SCHEMBL587488

CC(C)C(F)C(N)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20440144 1.00
SCHEMBL27947942 0.79
SCHEMBL30508151 0.76
SCHEMBL1031550 0.76
SCHEMBL3283687 0.73
SCHEMBL28758607 0.73
Hydrochloric Acid SCHEMBL27553220 0.71
SCHEMBL2995714 0.71
SCHEMBL21417686 0.71
SCHEMBL6973206 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192673-A1 Compounds STEP PHARMA S.A.S. (FR) 2023-06-22 US disclosed
US-20230086703-A1 N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases STEP PHARMA S.A.S. (FR) 2023-03-23 US disclosed
WO-2021237121-A1 SUBSTITUTED PYRIDINES GOSSAMER BIO SERVICES, INC. (US) 2021-11-25 WO disclosed
WO-2020115190-A1 NOVEL ANTIBACTERIAL 3\"-DERIVATIVES OF 4,6-DISUBSTITUTED 2,5-DIDEOXYSTREPTAMINE AMINOGLYCOSIDE ANTIBIOTICS AGILEBIOTICS B.V. (NL) 2020-06-11 WO disclosed
CN-110177786-A Pyrazolo [1,5-A] pyridine compounds being substituted are as RET kinase inhibitor 阿雷生物药品公司 2019-08-27 CN disclosed
CN-105828610-B Pesticidal compositions and methods related thereto 美国陶氏益农公司 2019-07-19 CN disclosed
CN-104603113-A Novel 2, 3-dihydro-1H-imidazo {1,2-a } pyrimidin-5-one and 1,2,3, 4-tetrahydropyrimidino {1,2-a } pyrimidin-6-one derivatives comprising substituted morpholines, preparation thereof and pharmaceutical use thereof SANOFI SA 2015-05-06 CN disclosed
EP-2416765-A1 HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS PTC Therapeutics, Inc. (US) 2012-02-15 EP disclosed
WO-2010117939-A1 HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS SCHERING CORPORATION (US) 2010-10-14 WO disclosed